Tweet
Virusdisease
. 2021 Mar 17;1-6.
doi: 10.1007/s13337-021-00679-2. Online ahead of print.
Respiratory delivery of favipiravir-tocilizumab combination through mucoadhesive protein-lipidic nanovesicles: prospective therapeutics against COVID-19
Vikram Thakur 1 , Radha Kanta Ratho 1 , Jiban Jyoti Panda 2
Affiliations
- PMID: 33748347
- PMCID: PMC7966910
- DOI: 10.1007/s13337-021-00679-2
Abstract
Coronavirus disease 19 (COVID-19) is the prime global health concern of the year 2020. Infecting more than 112 million individuals so far, this pandemic has already reported more than 2.4 million deaths around the world. With such high infectivity and mortality, effective treatment intervention is the need of the hour. The integration of medical science with nanotechnology may solve the current problem by exploring collective benefits. In this manuscript, we theoretically proposed the duo-combination of an approved antiviral i.e. favipiravir along with an immunomodulator i.e. tocilizumab loaded in protein-lipid nanovesicles as an effective anti-COVID-19 therapeutic. This proposed nanomedicine delivered through the respiratory mode may enhance the effectiveness of the antiviral and help in restricting the virus and associated complications, utilizing both anti-viral activity and immunomodulation in COVID-19 patients. This proposed nanomedicine could be an effective treatment modality for the severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2) infected patients.
Keywords: COVID-19; Favipiravir; Nanomedicine; Nanovesicles; Respiratory; SARS-CoV-2.